JZP385-202: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkin

Grants and Contracts Details

StatusActive
Effective start/end date8/17/238/17/25

Funding

  • Cavion Incorporated: $23,057.00